Oncoqr Ml Gmbh

Christopher Taus

Geert Mudde

Jorge Sepulveda

Liesbeth Mudde-Boer

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. an immunogen comprising an extracellular Her2/neu domain that is linked to a second peptidic alpha-helix coiled to the first alpha-helix; The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating Her2/neu positive tumor diseases.

Her2/neu immunogenic composition

A connector of a helical coiled coil-type structure connecting a first and a second molecule, wherein the first molecule comprises a peptidic first alpha-helix and the second molecule comprises a peptidic second alpha-helix, which second alpha-helix is coiled to the first alpha-helix. The first alpha-helix comprises a C-terminal region consisting of a repeat of an amino acid motif a-xand the C-terminal motif a-x-x, or an N-terminal region consisting of a repeat of an amino acid motif x-a and the N-terminal motif x-x-a, where a is a motif sequence of 4-8 amino acids, xis Lysine, and xis an extension of the motif. The extension consists of 1-10 amino acids and does not comprise more than 4 consecutive amino acids incorporated in said motif a-xor x-a. In a multimeric protein, two polypeptide chains can be connected to each other by such connector.

Growing community of inventors

Vienna, Austria

Christopher Taus